MX2010006243A - Moduladores de gamma secretasa. - Google Patents

Moduladores de gamma secretasa.

Info

Publication number
MX2010006243A
MX2010006243A MX2010006243A MX2010006243A MX2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A
Authority
MX
Mexico
Prior art keywords
gamma secretase
formula
secretase modulators
compounds
methods
Prior art date
Application number
MX2010006243A
Other languages
English (en)
Inventor
John Clader
William J Greenlee
Zhaoning Zhu
Zhiqiang Zhao
Xianhai Huang
Dmitri Pissarnitski
Anandan Palani
Xiaohong Zhu
Jun Qin
Robert G Aslanian
Mihirbaran Mandal
Thomas Bara
Chad E Bennett
Hubert Josien
Pawan Dhondi
Wei Zhou
Troy Mccracken
Duane Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006243A publication Critical patent/MX2010006243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Está invención provee compuestos que son moduladores de gamma secretasa; los compuestos de la fórmula I (ver fórmula (I)) en donde R2 es un anillo bicíclico condensado de la fórmula (II) (ver fórmula (I)) se exponen también métodos de modular la actividad de gamma secretasa y métodos de tratar la enfermedad de Alzheimer usando los compuestos de la fórmula (I).
MX2010006243A 2007-12-06 2008-12-04 Moduladores de gamma secretasa. MX2010006243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99283907P 2007-12-06 2007-12-06
PCT/US2008/085515 WO2009073777A1 (en) 2007-12-06 2008-12-04 Gamma secretase modulators

Publications (1)

Publication Number Publication Date
MX2010006243A true MX2010006243A (es) 2010-08-31

Family

ID=40351934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006243A MX2010006243A (es) 2007-12-06 2008-12-04 Moduladores de gamma secretasa.

Country Status (13)

Country Link
US (1) US8450343B2 (es)
EP (1) EP2229381A1 (es)
JP (1) JP2011506335A (es)
KR (1) KR20100094554A (es)
CN (1) CN101939315A (es)
AR (1) AR069635A1 (es)
AU (1) AU2008333865A1 (es)
CA (1) CA2707712A1 (es)
IL (1) IL206172A0 (es)
MX (1) MX2010006243A (es)
PE (1) PE20091095A1 (es)
TW (1) TW200930366A (es)
WO (1) WO2009073777A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AU2010211109B2 (en) 2009-02-06 2014-11-27 Cellzome Limited Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2010218714A1 (en) 2009-02-26 2011-09-08 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
MY152998A (en) 2009-05-07 2014-12-31 Janssen Pharmaceuticals Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
US20120142672A1 (en) * 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
MX2012000763A (es) * 2009-07-15 2012-02-08 Janssen Pharmaceuticals Inc Derivados sustituidos de triazol e imidazol como moduladores de la gamma secretasa.
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
CN105837401A (zh) * 2010-07-22 2016-08-10 兴和株式会社 光学活性1-溴-1-［3,5-双（三氟甲基）苯基］乙烷的制备方法
UY33586A (es) * 2010-09-02 2012-03-30 Takeda Pharmaceutical Compuesto heterocíclico y sus usos
CA2824013A1 (en) 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel bicyclic compound or salt thereof
US9120780B2 (en) * 2011-01-07 2015-09-01 Taiho Pharmaceutical Co., Ltd. Indole or indazole derivative or salt thereof
US8987276B2 (en) 2011-03-24 2015-03-24 Janssen Pharmaceuticals, Inc. Substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
KR101913135B1 (ko) * 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
WO2013066740A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Gamma secretase modulators
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
EP2914597B1 (en) 2012-10-31 2017-12-06 RaQualia Pharma Inc Pyrazolopyridine derivatives as ttx-s blockers
CN104837839A (zh) 2012-11-08 2015-08-12 辉瑞公司 作为多巴胺d1配体的杂芳族化合物
BR112015010620A2 (pt) 2012-11-08 2017-07-11 Pfizer compostos heteroaromáticos e seus usos como ligantes de dopamina d1
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
KR101689394B1 (ko) * 2013-12-12 2016-12-23 주식회사 종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 아자인돌 유도체 및 이를 포함하는 약제학적 조성물
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
LT3288940T (lt) * 2015-04-29 2021-05-10 Janssen Pharmaceutica Nv Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių
KR20170141768A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EA202091835A1 (ru) 2018-01-31 2020-10-20 Янссен Сайенсиз Айрлэнд Анлимитед Компани Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
ES2957316T3 (es) 2018-04-23 2024-01-17 Janssen Sciences Ireland Unlimited Co Compuestos heteroaromáticos que tienen actividad contra VSR
US20220048987A1 (en) * 2020-08-13 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Method of treatment to prevent or reverse age-associated inflammation, cognitive decline, and neurodegeneration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026712A (en) * 1985-06-05 1991-06-25 Schering Ag Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
US4937258A (en) * 1989-09-12 1990-06-26 Berlex Laboratories, Inc. Pyrrolo[1,2-c]imidazolone derivatives as PDE inhibitors
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1697369A1 (en) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
TWI335816B (en) * 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy

Also Published As

Publication number Publication date
US8450343B2 (en) 2013-05-28
EP2229381A1 (en) 2010-09-22
AU2008333865A2 (en) 2010-07-29
KR20100094554A (ko) 2010-08-26
AU2008333865A1 (en) 2009-06-11
CA2707712A1 (en) 2009-06-11
IL206172A0 (en) 2010-12-30
PE20091095A1 (es) 2009-07-25
TW200930366A (en) 2009-07-16
WO2009073777A1 (en) 2009-06-11
CN101939315A (zh) 2011-01-05
JP2011506335A (ja) 2011-03-03
US20110015190A1 (en) 2011-01-20
AR069635A1 (es) 2010-02-10

Similar Documents

Publication Publication Date Title
MX2010006243A (es) Moduladores de gamma secretasa.
MX2010002674A (es) Moduladores de gamma secretasa.
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2010005028A (es) Moduladores de gamma secretasa.
MX2010006046A (es) Moduladores de gamma secretasa.
CY1117014T1 (el) Παραγωγο συμπυκνωμενης αμινοδιυδροθιαζινης
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
HK1104813A1 (en) Fused ring azadecalin glucocorticoid receptor modulators
HK1146056A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
EA201290323A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
HK1146053A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
ZA200605634B (en) Azadecalin glucocorticoid receptor modulators
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2019007104A (es) Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2010001501A (es) Moduladores de gamma secretasa.
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MXPA06000957A (es) Compuestos de n-sulfonil heterociclopirrolilalquilamina como ligandos de 5-hidroxitriptamina-6.
WO2010147969A3 (en) Gamma secretase modulators
MY180131A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal